# TAPUR (NCT02693535)

> TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02693535
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: American Society of Clinical Oncology
- Conditions: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
- Interventions: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT); Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT); Olaparib (CLOSED TO ENROLLMENT); Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT); Abemaciclib (CLOSED TO ENROLLMENT); Talazoparib (CLOSED TO ENROLLMENT); Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT); Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT); Futibatinib; Dabrafenib plus Trametinib; Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Enrollment: 4200
- Primary outcome: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

## Commentary we found

- X threads: 128
- YouTube: 13
- Podcasts: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tapur-nct02693535

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02693535", "email": "<work email>"}; the inbox owner confirms by the emailed link.